High-dose chemotherapy in advanced breast cancer

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 2, 2002, Pages 141-149

  Viens, Patrice ^a,b   Maraninchi, Dominique ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Alkylating agent; Breast cancer; High dose chemotherapy

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; MELPHALAN; MITOXANTRONE; THIOTEPA; VINCRISTINE;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DRUG MEGADOSE; HUMAN; INFLAMMATORY DISEASE; METASTASIS; PATHOLOGY; PILOT STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GROWTH SUBSTANCES; HEMATOPOIETIC STEM CELLS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036173811     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00151-2     Document Type: Review

References (56)

1. Preclinical studies and clinical correlation of the effect of alkylating dose
2. Dose: a critical factor in cancer chemotherapy
3. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
4. The importance of dose intensity in chemotherapy of metastatic breast cancer
5. Treatment of Estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support
6. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report
7. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
8. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer
9. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
10. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer
11. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer
12. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
13. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients
14. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation
15. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial
16. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
17. Randomized trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
18. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
19. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial
20. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
21. Inflammatory breast carcinoma incidence and survival. The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992
22. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast
23. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma
24. First line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (Pegase 02 trial)
25. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome
26. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer
27. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer
28. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients
29. Two years of high-dose cyclophosphamide and 5-Fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months
30. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy
31. Prognostic factors in inflammatory breast cancer and therapeutic implications
32. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis
33. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave Roussy
34. Pathological assessment of response to induction chemotherapy in breast cancer
35. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer
36. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?
37. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer
38. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells
39. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
40. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasability and efficacy
41. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy
42. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node- positive breast cancer: a phase II study
43. Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer
44. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer
45. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results
46. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
47. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer
48. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation
49. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study
50. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy
51. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant
52. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer